Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have…
A woman carries a baby as she reacts after evacuating from Russian troop-occupied Kupiansk town in a bus convoy, amid Russia’s attack on Ukraine, on the outskirts of Kharkiv, Ukraine May 30, 2022. Picture taken May 30, 2022. Ivan Alvarado | Reuters Four years of war between Russia and Ukraine are beginning to take their…
World leaders during the G7 Leaders’ Summit in Kananaskis, in Alberta, Canada, June 17, 2025. Amber Bracken |Reuters U.S. trading partners offered a cautious welcome to the U.S. Supreme Court’s decision Friday to strike down large parts of President Donald Trump’s flagship trade policy on global tariffs — but global trade bodies warned of lingering…
The Supreme Court in Washington, Jan. 27, 2026. Al Drago | Bloomberg | Getty Images The Supreme Court may decide the fate of President Donald Trump’s tariff agenda as soon as Friday — and the ruling has implications for consumers’ wallets, according to economists. If the high court were to rule that certain tariffs are…
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive…
Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026. Oscar Molina | CNBC Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December….
The stock market is well-positioned to bounce next week if the heavyweight companies set to report earnings deliver strong numbers, CNBC’s Jim Cramer said Friday. That’s because the market ended the week on a subdued note, the “Mad Money” host said, after the S&P 500 finished in the red for three straight days. The busy…
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone. Top executives from drugmakers big and small told CNBC that the next phase…
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference — the biggest gathering of biotech and pharma execs, investors and analysts in…
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy….
